Novavax Inc (NVAX)
7.32
+0.10
(+1.38%)
USD |
NASDAQ |
Nov 15, 16:00
7.33
+0.01
(+0.14%)
After-Hours: 20:00
Novavax Research and Development Expense (TTM): 451.49M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 451.49M |
| June 30, 2024 | 470.55M |
| March 31, 2024 | 583.08M |
| December 31, 2023 | 737.50M |
| September 30, 2023 | 830.66M |
| June 30, 2023 | 1.029B |
| March 31, 2023 | 1.099B |
| December 31, 2022 | 1.235B |
| September 30, 2022 | 1.940B |
| June 30, 2022 | 2.044B |
| March 31, 2022 | 2.325B |
| December 31, 2021 | 2.535B |
| September 30, 2021 | 1.973B |
| June 30, 2021 | 1.859B |
| March 31, 2021 | 1.323B |
| December 31, 2020 | 747.03M |
| September 30, 2020 | 375.17M |
| June 30, 2020 | 99.69M |
| March 31, 2020 | 95.26M |
| December 31, 2019 | 113.84M |
| September 30, 2019 | 127.92M |
| June 30, 2019 | 150.63M |
| March 31, 2019 | 164.76M |
| December 31, 2018 | 173.80M |
| September 30, 2018 | 180.04M |
| Date | Value |
|---|---|
| June 30, 2018 | 180.57M |
| March 31, 2018 | 175.30M |
| December 31, 2017 | 168.44M |
| September 30, 2017 | 169.88M |
| June 30, 2017 | 181.00M |
| March 31, 2017 | 206.64M |
| December 31, 2016 | 237.94M |
| September 30, 2016 | 262.74M |
| June 30, 2016 | 240.42M |
| March 31, 2016 | 203.25M |
| December 31, 2015 | 162.64M |
| September 30, 2015 | 132.22M |
| June 30, 2015 | 120.78M |
| March 31, 2015 | 108.25M |
| December 31, 2014 | 94.42M |
| September 30, 2014 | 73.48M |
| June 30, 2014 | 68.21M |
| March 31, 2014 | 63.79M |
| December 31, 2013 | 58.53M |
| September 30, 2013 | 43.63M |
| June 30, 2013 | 36.32M |
| March 31, 2013 | 30.91M |
| December 31, 2012 | 26.99M |
| September 30, 2012 | 22.24M |
| June 30, 2012 | 19.65M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
95.26M
Minimum
Mar 2020
2.535B
Maximum
Dec 2021
1.093B
Average
929.69M
Median
Research and Development Expense (TTM) Benchmarks
| Pfizer Inc | 10.60B |
| Moderna Inc | 4.827B |
| Inovio Pharmaceuticals Inc | 76.76M |
| Baxter International Inc | 754.00M |
| Halozyme Therapeutics Inc | 79.94M |